Together, these findings pave the way for future investigation of combining BCL-2 and MCL-1 blockade to overcome multiple resistant MCL phenotypes, including those relapsed from anti-CD19 CAR T-cell therapy. This evidence concerns the gene CD19 and mantle cell lymphoma.